Findings

What do systematic reviews say?

537 questions · 560 findings · 45 reviews · Common Mental Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 105 · 18.8%GRADE not reported 8 · 1.4%Very low 170 · 30.4%Low 153 · 27.3%Moderate 94 · 16.8%High 30 · 5.4%

Benzodiazepines vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 75 participants
Low

Beta‐blockers vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD

It is very uncertain whether comparison 6: beta‐blockers changes global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (very low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 1.09 [0.63, 1.88]
2 studies · 97 participants
Very low

MAOIs vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD

Comparison 7: MAOIs may leads to higher global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 2.36 [1.48, 3.75]
4 studies · 235 participants
Low

MAOIs vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 218 participants
Very low

MAOIs vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 51 participants
Very low

MAOIs vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 51 participants
Very low

MAOIs vs placebo

Clinical Global Impressions scale change item (CGI‐I): no. of responders (long term) Post‐treatment: 1‐4 months · adults with SAnD

It is very uncertain whether comparison 7: MAOIs changes clinical Global Impressions scale change item (CGI‐I):no. of… compared with placebo (very low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 1.84 [1.02, 3.33]
2 studies · 113 participants
Very low

Comparison 8: NARIs vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD

It is very uncertain whether comparison 8: NARIs changes global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (very low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 0.7 [0.19, 2.54]
1 study · 27 participants
Very low

Comparison 1: 5HT1A partial agonists vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Very low

Comparison 8: NARIs vs placebo

Withdrawals due to adverse events · adults with SAnD

It is very uncertain whether comparison 8: NARIs changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 2.8 [0.12, 63.2]
1 study · 27 participants
Very low

Comparison 8: NARIs vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Very low

Comparison 9: NaSSAs vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD

It is very uncertain whether comparison 9: NaSSAs changes global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (very low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 1 [0.28, 3.63]
1 study · 60 participants
Very low

Comparison 9: NaSSAs vs placebo

Withdrawals due to adverse events · adults with SAnD

It is very uncertain whether comparison 9: NaSSAs changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 5 [0.25, 99.95]
1 study · 60 participants
Very low

Comparison 9: NaSSAs vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 126 participants
Very low

Comparison 9: NaSSAs vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Low

Comparison 9: NaSSAs vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Low

Comparison 10: RIMAs vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD

Comparison 10: RIMAs may leads to higher global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 1.83 [1.32, 2.55]
8 studies · 1270 participants
Low

Comparison 10: RIMAs vs placebo

Withdrawals due to adverse events · adults with SAnD

It is very uncertain whether comparison 10: RIMAs changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 1.42 [0.86, 2.34]
8 studies · 1305 participants
Very low

Comparison 10: RIMAs vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 1163 participants
Very low

Comparison 2: anticonvulsants/GABAs vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD

Comparison 2: anticonvulsants/GABAs probably leads to higher global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (moderate certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 1.6 [1.16, 2.2]
3 studies · 532 participants
Moderate